Investing Experience -
Risk Profile -
Followers
0
Following
0
Blog Posts
0
Threads
5,968
Blogs
Threads
Portfolio
Follower
Following
Summary
Total comments
5,968
Past 30 days
0
Past 7 days
0
Today
0
User Comments
General
2020-12-15 12:00 | Report Abuse
China’s November factory output rises for 8th straight month as recovery gathers pace
(PUBLISHED MON, DEC 14 20209:52 PM EST)
~ China’s industrial output grew in line with expectations in November, expanding for the eighth straight month as the economic recovery gathered pace and global demand picked up.
~ Industrial output growth quickened to 7.0% in November from a year earlier, data from the National Statistics Bureau showed on Tuesday. That was in line with analyst expectations in a Reuters poll and faster than the 6.9% expansion in October.
~ China’s economy has staged an impressive recovery from its Covid-19 paralysis earlier this year, mainly driven by robust exports.
China’s industrial output grew in line with expectations in November, expanding for the eighth straight month as the economic recovery gathered pace and global demand picked up.
Industrial output growth quickened to 7.0% in November from a year earlier, data from the National Statistics Bureau showed on Tuesday. That was in line with analyst expectations in a Reuters poll and faster than the 6.9% expansion in October.
China’s economy has staged an impressive recovery from its Covid-19 paralysis earlier this year, mainly driven by robust exports.
An annual sales promotion extravaganza in November by China’s e-commerce giants has also open consumers’ wallets in a further boost to orders for small factories.
Retail sales rose 5% on-year, just missing analysts’ forecast for 5.2% growth but faster than the 4.3% increase in October.
Auto sales saw 11.8% growth and sales of household appliances grew 5.1% in November. Communications equipment sales jumped by 43.6%.
Fixed-asset investment rose 2.6% in January-November from the same period last year, in line with a forecast 2.6% growth and faster than a 1.8% increase in the first 10 months of 2020.
Private-sector fixed-asset investment, which accounts for 60% of total investment, rose 0.2% in January-November, compared with a 0.7% decline in the first 10 months of the year.
China’s economic recovery looks to be accelerating in the fourth quarter, driven by stronger demand, credit growth and stimulus measures expected to provide a strong tailwind into 2021.
Factory activity growth hit a more than three-year high in November, an official survey showed, as fewer Covid-19 infections boosted consumer confidence.
Exports also surged at their fastest pace in almost three years thanks to hot demand for personal protective equipment and electronics products for working from home.
However, tougher measures to contain the coronavirus imposed by the country’s trading partners have created shipping bottlenecks, pushing up transportation costs and capping the speed of China’s recovery.
##https://www.cnbc.com/2020/12/15/chinas-november-factory-output-rises-for-8th-straight-month.html
Stock
2020-12-15 09:49 | Report Abuse
Even though you all plan to keep it for long term...
But not at this point since overall this counter sentiment remained very very weak...
Don't burnt your hard earned money......
For more safety margin better be more patience until below 3.00 then decide again......
Fyi, for the past few years record range, 1.30 ~ 1.60.....
Only this year more speculation then shot up above 4.00......
Stock
2020-12-15 09:35 | Report Abuse
Further downside risk towards 2.80 ~ 3.00......
If unable to support, further downside risk towards 2.55 ~ 2.65...
Don't be hero to fight current level......
Stock
2020-12-14 21:54 | Report Abuse
Keyman188 no plan to sell......
See you @ 12.00......
CHEERS......
Stock
2020-12-14 21:52 | Report Abuse
Keyman188 no plan to sell.......
See you @ 5.00......
See you give Keyman188 bonus reward......
Stock
2020-12-14 18:50 | Report Abuse
Keyman188 no plan to sell...
See you @ 2.00......
CHEERS......
Stock
2020-12-14 17:25 | Report Abuse
Keyman188 still can recall...
Past few months back during MCO...CMCO...or...lock down everywhere...
TG players very happy & laughing others who are suffering because all other sectors so much selling pressure until no eye see...
But now come back to TG become heavily selling pressure due to factory CMCO + penalty once if found guilty on SOP not meet...
Right now more worsen, top investment bank in the world (JP Morgan) had revised lower target price to reflect upcoming earnings prospects...
So end up TG this few weeks become targeted share price turbulence & turmoil...
Is it called karma + retribution!!!...
For those unable to take current challenging better avoid glove sector, otherwise you need to visit Psychiatrists soon......
人在做...天在看...
Stock
2020-12-14 14:18 | Report Abuse
Very high possibility downside risk to RM 1.80 ~ RM 2.00 for the next 12 months...
R.I.P....
Stock
2020-12-14 14:10 | Report Abuse
Banking stocks top gainers list as investors switch to recovery plays on vaccine distribution
(theedgemarkets.com / December 14, 2020 13:11 pm +08)
KUALA LUMPUR (Dec 14): Banking stocks continue to dominate the list of top gainers, as investors switched to recovery plays following the Covid-19 vaccine rollout.
At noon break, Public Bank Bhd rose 66 sen or 3.01% to RM22.56, making it the second top gainer. This was followed by Hong Leong Bank Bhd, which gained 62 sen or 3.26% to RM19.62.
CIMB Group Holdings Bhd, which was also among the top gainers this morning, climbed 26 sen or 5.84% to RM4.71.
TA Securities’ analyst Li Hsia Wong said in a report today the firm had an "overweight" call on the banking sector underpinned by a more positive outlook in domestic economic activities, some uplift in net interest margin on the back of the gradual unwinding of modification loss and more stable interest rates environment, concerted stimulus measures by governments globally to protect businesses and individuals from economic disruptions caused by the Covid-19 pandemic, and potential reopening of borders as countries look into a mass vaccine rollout.
“Despite uncertainties in terms of the credit outlook, especially post the loan moratorium, we believe that the continued repayment and debt rehabilitation support for targeted borrowers should help address earlier concerns over the broader impact from a potential cliff effect,” said Li.
Coming from a low base, Li forecast banking sector profit growth of 17.7% and 18% in 2021 and 2022 respectively.
“We expect the sector to register a 27.7% year-on-year decline in 2020 net profit. With that, we lower our market risk premium assumption to 5.5% from 6.5%,” said Li.
Li has "buy" calls on Malayan Banking Bhd (target price: RM10.80), Public Bank (TP: RM25.10), CIMB (TP: RM5.10), Hong Leong Bank (TP: RM23), RHB Bank Bhd (TP: RM7), AMMB Holdings Bhd (TP: RM4.50), Alliance Bank Malaysia Bhd (TP: RM3.70) and Affin Bank Bhd (TP: RM2.50).
##https://www.theedgemarkets.com/article/banking-stocks-top-gainers-list-investors-switch-recovery-plays-vaccine-distribution
General
2020-12-14 14:10 | Report Abuse
Banking stocks top gainers list as investors switch to recovery plays on vaccine distribution
(theedgemarkets.com / December 14, 2020 13:11 pm +08)
KUALA LUMPUR (Dec 14): Banking stocks continue to dominate the list of top gainers, as investors switched to recovery plays following the Covid-19 vaccine rollout.
At noon break, Public Bank Bhd rose 66 sen or 3.01% to RM22.56, making it the second top gainer. This was followed by Hong Leong Bank Bhd, which gained 62 sen or 3.26% to RM19.62.
CIMB Group Holdings Bhd, which was also among the top gainers this morning, climbed 26 sen or 5.84% to RM4.71.
TA Securities’ analyst Li Hsia Wong said in a report today the firm had an "overweight" call on the banking sector underpinned by a more positive outlook in domestic economic activities, some uplift in net interest margin on the back of the gradual unwinding of modification loss and more stable interest rates environment, concerted stimulus measures by governments globally to protect businesses and individuals from economic disruptions caused by the Covid-19 pandemic, and potential reopening of borders as countries look into a mass vaccine rollout.
“Despite uncertainties in terms of the credit outlook, especially post the loan moratorium, we believe that the continued repayment and debt rehabilitation support for targeted borrowers should help address earlier concerns over the broader impact from a potential cliff effect,” said Li.
Coming from a low base, Li forecast banking sector profit growth of 17.7% and 18% in 2021 and 2022 respectively.
“We expect the sector to register a 27.7% year-on-year decline in 2020 net profit. With that, we lower our market risk premium assumption to 5.5% from 6.5%,” said Li.
Li has "buy" calls on Malayan Banking Bhd (target price: RM10.80), Public Bank (TP: RM25.10), CIMB (TP: RM5.10), Hong Leong Bank (TP: RM23), RHB Bank Bhd (TP: RM7), AMMB Holdings Bhd (TP: RM4.50), Alliance Bank Malaysia Bhd (TP: RM3.70) and Affin Bank Bhd (TP: RM2.50).
##https://www.theedgemarkets.com/article/banking-stocks-top-gainers-list-investors-switch-recovery-plays-vaccine-distribution
Stock
2020-12-14 12:27 | Report Abuse
Foresee more worst ahead for this whole week if more & more "victim" death......
Posted by Keyman188 > Dec 14, 2020 11:59 AM | Report Abuse
Top Glove reports death of worker due to Covid-19, first since outbreak at firm
(December 14, 2020 11:56 am +08)
KUALA LUMPUR (Dec 14): Top Glove Corp Bhd has reported that a worker died on Saturday due to Covid-19, the first death since the outbreak at its dormitories and factories in October.
##https://www.theedgemarkets.com/article/top-glove-reports-death-worker-...
Stock
2020-12-14 12:10 | Report Abuse
Top Glove reports death of worker due to Covid-19, first since outbreak at firm
(December 14, 2020 11:56 am +08)
KUALA LUMPUR (Dec 14): Top Glove Corp Bhd has reported that a worker died on Saturday due to Covid-19, the first death since the outbreak at its dormitories and factories in October.
##https://www.theedgemarkets.com/article/top-glove-reports-death-worker-due-covid19-first-outbreak-firm
^^^Seem like more worst ahead......
Stock
2020-12-14 12:09 | Report Abuse
Top Glove reports death of worker due to Covid-19, first since outbreak at firm
(December 14, 2020 11:56 am +08)
KUALA LUMPUR (Dec 14): Top Glove Corp Bhd has reported that a worker died on Saturday due to Covid-19, the first death since the outbreak at its dormitories and factories in October.
##https://www.theedgemarkets.com/article/top-glove-reports-death-worker-due-covid19-first-outbreak-firm
^^^Seem like more worst ahead......
News & Blogs
2020-12-14 12:02 | Report Abuse
Top Glove reports death of worker due to Covid-19, first since outbreak at firm
(December 14, 2020 11:56 am +08)
KUALA LUMPUR (Dec 14): Top Glove Corp Bhd has reported that a worker died on Saturday due to Covid-19, the first death since the outbreak at its dormitories and factories in October.
##https://www.theedgemarkets.com/article/top-glove-reports-death-worker-due-covid19-first-outbreak-firm
Stock
2020-12-14 11:59 | Report Abuse
Top Glove reports death of worker due to Covid-19, first since outbreak at firm
(December 14, 2020 11:56 am +08)
KUALA LUMPUR (Dec 14): Top Glove Corp Bhd has reported that a worker died on Saturday due to Covid-19, the first death since the outbreak at its dormitories and factories in October.
##https://www.theedgemarkets.com/article/top-glove-reports-death-worker-due-covid19-first-outbreak-firm
General
2020-12-14 11:56 | Report Abuse
Stocks could see all-time highs before year-end, top strategist says. How he’d play it
(PUBLISHED SUN, DEC 13 20205:00 PM EST)
Stocks could make another run at record highs before the year is out, says one top strategist.
The major averages closed in the red on Friday after a week marked by uncertainty around congressional stimulus talks. But while the market does face near-term hurdles, new highs are not far out of reach, Federated Hermes chief equity market strategist Phil Orlando told CNBC’s “Trading Nation.”
“There could be some more chop over the next week or so,” Orlando said in a Friday interivew.
He cited the market’s recent record rally — the S&P 500 is up 12% since the beginning of November — as well as the latest spike in Covid-19 cases, congressional budget discussions, stimulus talks, an upcoming Brexit deadline and the Senate runoff races in Georgia as the headline risks in the coming weeks.
“We’re optimistically saying that we’re going to get through some of these hurdles near term and get to that 3,800 level by the end of the year,” Orlando said.
“There’s a lot of good things in the pipeline if things break right,” particularly on the Covid vaccine front, he said. “We’ve got to get through a couple of these hurdles over the next few weeks and, to a significant degree, that will determine the pace of continued improvement over the course of calendar ’21.”
At this point, one of two things would persuade Orlando to add to his firm’s 4% overweight exposure to equities.
“There are two things we’re waiting for, either some resolution on some of these hurdles that we’ve just laid out or perhaps better prices,” he said. “We’re being very patient. And either a resolution of those issues or better prices will allow us to step in and put some more money to work.”
For him, a 5-10% market decline coupled with a “relatively smooth” vaccine rollout in the United States “would be enticing” enough for him to up Federated’s exposure to stocks, he said.
“We’re not going to force this. From where the market is right now through the end of next year, we think we can do 15% or so to our 4,200 target on a total return basis and that’s pretty good,” Orlando said. “At this point, we’re just going to be patient and let the market come to us.”
If it does, Orlando said he would stick with his firm’s strategy from mid-August when buying into the market. Federated had $615 billion in assets under management as of the third quarter.
“At that point, we felt that domestic large-cap growth stocks, largely led by technology, had gotten ahead of themselves. We took that sector back to neutral and allocated the money into three other areas — domestic large-cap value, small caps and international,” he said.
The gap between large-cap growth and the other side of Federated’s strategy was so large “that we think that that trade will continue to bear some fruit,” Orlando said.
“So, as we’re putting new money to work, it’s those three areas — international, domestic large-cap value and domestic small cap — that we think would get the incremental dollar at this point in terms of what we think will play out over the course of the next year,” he said.
##https://www.cnbc.com/2020/12/13/stocks-to-see-all-time-highs-before-year-ends.html
Stock
2020-12-13 22:27 | Report Abuse
Aiya...no need border can break 1.00 or not...
Keyman188 no plan to sell unless can reach above 2.80 then reconsider to sell all lorrr...
Stock
2020-12-13 21:41 | Report Abuse
Aiya...sure buy TG lahhh...
Since we are now at TG forum & some more so hot everyday....
Kekeke...
Posted by AllYouCanBuy > Dec 13, 2020 9:09 PM | Report Abuse
@Keyman188 So which recovery stocks do you suggest buying??
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
Stock
2020-12-13 20:50 | Report Abuse
No worry...if tomorrow further big drop...
TSLWC sure will approach his biz partners or friends to buy in further...
Same practice to Tropicana mahhh...
Sure will say value for long term investment mahhh...
News & Blogs
2020-12-13 19:45 |
Post removed.Why?
Stock
2020-12-13 19:41 | Report Abuse
YA...Keyman188 also can't sleep because feel very excited tomorrow...kekeke
Stock
Stock
Stock
2020-12-13 19:11 | Report Abuse
Genting-backed biotech firm completes first assessment of Covid-19 treatment trial
theedgemarkets.com / December 13, 2020 18:09 pm +08
KUALA LUMPUR (Dec 13): Genting Bhd’s biotechnology arm Celularity Inc said its independent data monitoring committee (DMC) had completed the first assessment of an ongoing study of natural killer (NK) cell therapy in adults with Covid-19 and that the observed clinical findings justify the continuation of the trial of the potential therapeutic treatment for Covid-19 patients with limited treatment options.
In its latest statement on Dec 1, US-based Celularity said the Phase I/II CYNK-001-Covid-19 clinical trial is continuing to enroll to the next evaluation milestone where the external, independent DMC would review the Phase I data for both safety and efficacy.
"Celularity continues to accumulate safety data on CYNK-001 across a broad platform of programmes, including Covid-19 as well as haematologic and solid tumour malignancies.
"NK cells are innate immune cells with an important role in early host response against various pathogens. Multiple NK cell receptors are involved in the recognition of infected cells. Studies in humans and mice have established that there is robust activation of NK cells during viral infection, regardless of the virus class, and that the depletion of NK cells aggravates viral pathogenesis," the company said.
Celularity founder, chairman and chief executive officer (CEO) Robert J Hariri said in the statement that the administration of NK cells may have potential to both control viral infection while also coordinating a more effective immune response that could lead to strong and lasting protection against viruses.
Hariri said that with increasing incidence of Covid-19 nationwide, Celularity reaffirmed its commitment to the development of CYNK-001 as a potential therapeutic treatment for patients with limited treatment options.
"Through our collaboration with investigators, we anticipate rapid enrolment culminating in the next DMC review of safety and efficacy data,” he said.
Celularity was formed in February 2018 with a US$250 million (about RM1.01 billion) funding from several investors comprising Genting Group, Celgene, United Therapeutics, Sorrento Therapeutics, Human Longevity Inc, the Dreyfus Family Office, Section 32 and Heritage Group, according to Celularity’s statement on Feb 15, 2018.
Celularity’s statement, however, did not specify how much money hotel and casino operator Genting Group had invested in the biotechnology company.
According to Celularity’s website, Genting Bhd chairman and chief executive Tan Sri Lim Kok Thay is a director of Celularity.
Meanwhile, on Bursa Malaysia on Friday, Genting Bhd’s share price closed up 19 sen or 4.24% at RM4.67, with a market value of about RM17.98 billion.
The stock saw some 23 million shares traded.
##https://www.theedgemarkets.com/article/gentingbacked-biotech-firm-completes-first-assessment-covid19-treatment-trial
Stock
2020-12-13 19:10 | Report Abuse
Genting-backed biotech firm completes first assessment of Covid-19 treatment trial
theedgemarkets.com / December 13, 2020 18:09 pm +08
KUALA LUMPUR (Dec 13): Genting Bhd’s biotechnology arm Celularity Inc said its independent data monitoring committee (DMC) had completed the first assessment of an ongoing study of natural killer (NK) cell therapy in adults with Covid-19 and that the observed clinical findings justify the continuation of the trial of the potential therapeutic treatment for Covid-19 patients with limited treatment options.
In its latest statement on Dec 1, US-based Celularity said the Phase I/II CYNK-001-Covid-19 clinical trial is continuing to enroll to the next evaluation milestone where the external, independent DMC would review the Phase I data for both safety and efficacy.
"Celularity continues to accumulate safety data on CYNK-001 across a broad platform of programmes, including Covid-19 as well as haematologic and solid tumour malignancies.
"NK cells are innate immune cells with an important role in early host response against various pathogens. Multiple NK cell receptors are involved in the recognition of infected cells. Studies in humans and mice have established that there is robust activation of NK cells during viral infection, regardless of the virus class, and that the depletion of NK cells aggravates viral pathogenesis," the company said.
Celularity founder, chairman and chief executive officer (CEO) Robert J Hariri said in the statement that the administration of NK cells may have potential to both control viral infection while also coordinating a more effective immune response that could lead to strong and lasting protection against viruses.
Hariri said that with increasing incidence of Covid-19 nationwide, Celularity reaffirmed its commitment to the development of CYNK-001 as a potential therapeutic treatment for patients with limited treatment options.
"Through our collaboration with investigators, we anticipate rapid enrolment culminating in the next DMC review of safety and efficacy data,” he said.
Celularity was formed in February 2018 with a US$250 million (about RM1.01 billion) funding from several investors comprising Genting Group, Celgene, United Therapeutics, Sorrento Therapeutics, Human Longevity Inc, the Dreyfus Family Office, Section 32 and Heritage Group, according to Celularity’s statement on Feb 15, 2018.
Celularity’s statement, however, did not specify how much money hotel and casino operator Genting Group had invested in the biotechnology company.
According to Celularity’s website, Genting Bhd chairman and chief executive Tan Sri Lim Kok Thay is a director of Celularity.
Meanwhile, on Bursa Malaysia on Friday, Genting Bhd’s share price closed up 19 sen or 4.24% at RM4.67, with a market value of about RM17.98 billion.
The stock saw some 23 million shares traded.
##https://www.theedgemarkets.com/article/gentingbacked-biotech-firm-completes-first-assessment-covid19-treatment-trial
Stock
2020-12-13 19:05 | Report Abuse
Aiyo...time to wake up to switch recovery stocks lorrr......
Stock
2020-12-13 19:03 | Report Abuse
If local IB so confidence their target price, why 1 day can short sell 101 millions share?...
If only 2 foreign IB sell down, so local IB should be supported & push back whatever the local IB forecast their TP...
But seem like local IB also very doubt to support & perhaps some local IB also join the part to short sell...
Stock
2020-12-13 14:42 | Report Abuse
Don't run everyday...tired...
Better drive mahhh..........save human energy mahhh...
Stock
2020-12-13 14:39 | Report Abuse
Boleh track until T+10 geh ???
Stock
2020-12-13 14:36 | Report Abuse
OMG...seem like next week more selling pressure...
OMG...seem like next week more bleeding again......
kekeke...kekeke...
Stock
Stock
2020-12-13 13:59 | Report Abuse
Right now still not yet painful mahhh...
Until next month then see what you fell lorrr......
Stock
2020-12-13 13:58 | Report Abuse
Aiyo...IDSS sudah temporarily suspended quite sometime lahhh...
Suspension of short selling on Bursa Malaysia extended until year-end
(theedgemarkets.com / June 26, 2020 20:49 pm +08)
## https://www.theedgemarkets.com/article/suspension-short-selling-bursa-malaysia-extended-until-yearend
Stock
2020-12-13 13:54 | Report Abuse
Aiya...sometime too much of friends banyak kacau...
Give more spare time & place to yourself better mahhh...
wkwkwk...kekeke...
Stock
2020-12-13 13:50 | Report Abuse
That's why Keyman188 called "Keyman" lorrr...
Sometime copy this style...sometime copy other people style...
Then life become wonderful & not boring life mahhhh...
Posted by Stockhunter88 > Dec 13, 2020 1:47 PM | Report Abuse
Why keyman writing style so similar to stockraider?
Stock
2020-12-13 13:48 | Report Abuse
Keyman188 always deserve to become so hai kia also never mind mahhh...
So long as Keyman188 saw so hai kia jumping here & there to rescue himself definitely Keyman188 sure excited lorrrr......
So long as Keyman188 saw so hai kia loosing money definitely Keyman188 sure excited lorrrr......
kekeke...kekeke...wkwkwk...wkwkwk...
Stock
2020-12-13 13:42 | Report Abuse
We all can't give so much target price mahh....
Only AlvinTSK is sifu at TG forum mahhh...
So we better follow opposite direction from AlvinTSK sifu lorrr......
We all still infant mahhh...& still broke & poor investors mahhh......
So no choice lorrr...must be careful to invest lorr...
We all not like AlvinTSK sifu so big mouth to eat all falling knight pricing mahhh....
General
2020-12-13 13:38 | Report Abuse
China’s economic vulnerabilities to be focus of 2021 work conference amid strong GDP forecast, analysts say
~ Communist Party officials are expected to convene for the annual Central Economic Work Conference in coming days
~ With headline growth likely to be strong next year, the focus is expected to be on addressing domestic economic risk
China’s leaders are expected to prioritise fixing social and economic weak links in 2021 – the year the ruling Communist Party celebrates its 100th anniversary – when they gather to take stock of the country’s economic performance in coming days, analysts said.
President Xi Jinping and hundreds of party officials are set to convene for the annual Central Economic Work Conference in Beijing to settle policies and targets for next year.
While authorities do not release the conference schedule beforehand, it is clear from a flurry of state media reports – including a front-page People’s Daily story praising China’s economic performance under Xi’s leadership – that the meeting is near.
With headline gross domestic product (GDP) growth rate set to be strong next year thanks to a low base in 2020, the focus of the work conference will likely be tackling economic vulnerabilities to offset an unstable external environment, according to Chinese government researchers and scholars.
Beijing faces a range of pressing economic problems, including a mountain of local government debt, uneven economic recovery from the coronavirus pandemic and China’s testy relationship with the United States, which will enter a new chapter when Joe Biden assumes the presidency.
“We must pay great attention to a variety of risks in the first year of the five-year plan,” said Li Daokui, a Tsinghua University professor and former central bank adviser, referring to China’s 14th five-year plan for the period 2021-25.
Li told a forum in Beijing on Wednesday that the world’s second largest economy needs to be more “self-reliant” as part of its dual circulation strategy, which focuses on developing the domestic market for future growth.
China, where the coronavirus outbreak was first reported, has seen a V-shape economic recovery this year.
Most forecasts expect China to report a 2 per cent economic growth
this year, making it the only G20 economy to expand. But 2 per cent expansion is far below China’s potential annual growth rate of 6 per cent and lays the ground for a strong 2021.
Rating agency Fitch this week revised up its estimate for China’s 2021 GDP growth to 8 per cent.
China’s relative success in containing the Covid-19 pandemic and restarting its economy, in sharp contrast to the US and India, has been a source of pride for in Beijing, where only a year ago many were worried about the prospects for growth amid a bruising trade war with the US.
With GDP growing at 4.9 per cent in the third quarter
, after rebounding from a historic 6.8 per cent contraction in the first three months, Beijing is gaining fresh confidence in its development model.
But the country’s weak consumption and employment rate remained the economy’s soft underbelly, said Yu Chunhai, a professor of economics at Renmin University of China.
Social retail sales, a key indicator for consumer spending, fell 5.9 per cent in the 10 months of the year.
Many businesses in the services sector remain vulnerable, despite the impressive headline figures. The collapse of Youwin Education, a private tutoring company, triggered rare protests in Beijing’s central business district in October. A similar demonstration occurred outside the Beijing headquarters of Nasdaq-listed rental company Danke
last month, when the company failed to pay landlords it was renting properties from.
Many academic and policy advisers in Beijing are divided in their assessment of the Chinese economy and the reversal of stimulus measures.
The Bank of Communications, China’s fifth largest lender, expected further tapering of monetary policy. It estimated that aggregated financing growth would slow by 3 percentage points to about 11 per cent next year, while money supply growth would drop to 9 per cent from the current 10.7 per cent.
However, its chief analyst Tang Jianwei called for continued fiscal expenditure to support the economy, suggesting a fiscal deficit ratio of 3 per cent in 2021.
“There should be many key projects launched at the start of the five-year plan, a certain pace of fiscal expenditure is needed. It is also needed to offset the impact of credit tightening,” he said.
“The central government still has room to increase its leverage.”
##https://www.scmp.com/economy/china-economy/article/3113429/chinas-economic-vulnerabilities-be-focus-2021-work-conference
Stock
2020-12-13 13:30 | Report Abuse
Too sad to say...
Keyman188 only infant at the share market......
Everyday is Keyman188 1st day at the share market...
Posted by stkoay > Dec 13, 2020 1:28 PM | Report Abuse
Keyman188 has proven to be the real sifu
....ha...ha...
Stock
2020-12-13 13:28 | Report Abuse
So like that better sell lorrr....
AlvinTSK sifu always contradiction what his commented....
When AlvinTSK sifu asking you buy...then run...
Whan AlvinTSK sifu asking you sell...then bet in...
kekeke...kekeke...
KLCI Index Will Visit 1732 Level Soon & Next Challenge Level Shall Be 1796 Remarkable Level Soon
2020-12-15 12:21 | Report Abuse
Goldman, Citi, Nomura See 20% Earnings Growth for Asia Stocks in 2021
(December 15, 2020, 6:30 AM GMT+8)
While Asia’s equity rally may be ending the year looking a tad stretched, a bright earnings outlook for 2021 is giving strategists all the more reason to stay upbeat.
No less a trio than Citigroup Inc., Goldman Sachs Group Inc. and Nomura Holdings Inc. have penciled in earnings growth of more than 20% for Asian shares next year. Citi and Nomura are joined by Societe Generale SA in expectations for between a 5% and 7% rise in the MSCI Asia ex-Japan Index, while Goldman sees a 9% jump in the Asia Pacific equivalent in 2021.
“We remain optimistic about 2021 prospects driven by the macro and earnings recovery and would be buyers of any market pullbacks,” a team of Goldman strategists including Timothy Moe wrote in a note published on Sunday.
Asian stocks are finishing an unprecedented year in strong fashion with the MSCI Asia ex-Japan erasing its pandemic-related losses in the summer and surging to a 18% year-to-date rise through Monday. Benchmarks in technology-heavy South Korea and Taiwan have led the way.
For next year, the prospects for profit growth looks strongest in Korea, Citi analysts including Robert Buckland wrote in a note last week, projecting a whopping 43% jump in earnings-per-share growth for Korean stocks in 2021.
Read: Fund Manager Beating 97% of Peers Is Buying Korean Tech Stocks
Sector-wise, earnings growth is shifting to cyclical sectors, such as materials and financials, SocGen analysts including Frank Benzimra wrote in a note published last month.
2022 Time
Further boosting returns in Asian equities next year will be expectations of an earnings recovery in 2022, according to Goldman.
“With strong market returns this year and full valuations, the market has priced next year‘s earnings recovery: 2022 earnings will be the primary driver of 2021 returns,” the Goldman team wrote. It expects regional earnings to grow at 16% that year.
##https://www.bloomberg.com/news/articles/2020-12-14/20-plus-profit-growth-backs-asia-s-bull-case-taking-stocks?srnd=premium-asia